Water Tower Research said it had published a management series report on Aspen Aerogels (NYSE:ASPN), a company which has created a modified version of its aerogel insulation materials branded PyroThin used in lithium-ion batteries in electric vehicles. Click here to access the report.
Sigma Lithium Corp (TSX-V:SGML, OTCQB:SGMLF, NASDAQ:SGML) Co-CEO Ana Cabral-Gardner will present at the Bank of America (NYSE:BAC) Securities Virtual Battery and Storage Conference on January 10, 2022. The presentation, entitled Decarbonizing Lithium along with Autos, will take place on Monday, January 10, 2022 at 11:15 AM and webcast at https://bofa.veracast.com/webcasts/bofa/batterystorage2022/id6B9yZs.cfm. Cabral-Gardner will host one-on-one meetings throughout the day on Monday, January 10.
Progressive Planet Solutions Inc (TSX-V:PLAN) announced that the company will present a business update and further details regarding the acquisition of Absorbent Products LTD during a live Zoom webinar on Monday, January 10th at 4:00 p.m. EST/1:00 p.m. PST. PLAN will address the acquisition, evolving corporate developments, current highlights and future business objectives. Members of the Executive Team, including CEO Steve Harpur, will present and participate in a Q&A session. Shareholders are invited to register at this link. For those unable to participate, a recording of the webinar will be posted to the Progressive Planet Solutions website following the live broadcast.
Falcon Gold Corp (TSX-V:FG, OTC:FGLDF) CEO Karim Rayani issued a letter to shareholders, highlighting the achievements of 2021 while sharing details of the oncoming year. “As a new year begins, I would like to share some of our successes over the past year and objectives for the ensuing year,” said Rayani in the letter. “With the world scale pandemic continuing its attack on the globe, it can be sometimes hard to discern the clear road ahead. Despite all that is happening, my commitment remains the same to our company since the first day I signed on as chief executive officer.” He added: “My focus is and always has been on creating shareholder value, and it will be no different as we embark on a new year.” The Vancouver, British Columbia-based company said that it is "looking forward to a robust exploration season in 2022."
Minto Metals Corp (TSX-V:MNTO) revealed operational results for the 2021 year that show a 46% increase in copper production from its Minto mine in British Columbia compared to 2020 levels. The Whitehorse, Yukon-based firm said the Minto operation produced 26 million pounds of payable copper throughout the 12-month period to end December 31, 2021, compared to 17.8 million pounds last year. Minto delivered an average of 3,000 tonnes per day of ore processed through the mill and 6.1 million pounds of payable copper in November and December, which Minto Metals called a “strong finish” to the year.
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has told investors it expects to complete patient enrollment of its Phase 3 clinical trial for Bucillamine in coronavirus (COVID-19) in the first quarter of 2022. In a statement clarifying the status of the trial, the life sciences company noted that as of December 29 last year, there had been around 700 subjects who had "participated in the enrollment period" of the study. "In addition, the company has begun the process to expand the study’s patient population in Turkey in collaboration with Delta Health, which will add research sites from the largest hospital group in Turkey, MLP Care and Istinye University," it said in a brief statement.
Bragg Gaming Group (TSX:BRAG, NASDAQ:BRAG) Inc said its wholly-owned subsidiary ORYX Gaming has continued to grow its presence in the UK with the addition of its content to several casino brands operated by SkillOnNet in the market. The company said the partnership with SkillOnNet is the latest in a string of agreements that has seen ORYX rapidly establish a presence in the UK iGaming market following receipt of its supplier licence from the Gambling Commission in November. “We have hit the ground running in the UK and are thrilled to have partnered with a number of leading operators so swiftly after receiving our UK licence,” Bragg chief commercial officer Chris Looney said in a statement.
Trust Stamp (OTCQX:IDAI, EURONEXT:AIID) Inc, a provider of AI-powered trust and identity services across multiple industries, has announced the successful completion of a combined public and private fundraise totaling US$8.84 million. The Atlanta, Georgia-based company said it closed investments totaling $8.84 million through a combination of the fundraise and warrant executions, of which $59,212 is pending transfer from escrow and subject to cancellation. It added that 3,816,967 new shares of Class A common stock and 1,378,766 new warrants will have been issued upon completion of all transactions. Trust Stamp (OTCQX:IDAI, EURONEXT:AIID) said it has raised $30.05 million to date. In a statement, Trust Stamp (OTCQX:IDAI, EURONEXT:AIID) CEO Gareth N. Genner said: "Trust Stamp (OTCQX:IDAI, EURONEXT:AIID)'s unique proposition of privacy-first, secure, and accessible biometric and digital identity solutions continues to be validated with the support of both new and returning shareholders, strategic international partnerships, and cross-industry demand for our scaling portfolio of transformative identity, data protection, and fraud-prevention capabilities.”
Stifel GMP said it was encouraged to see the recent investment by The McQuade Center for Strategic Research and Development (MSRD) into Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF), which the broker said, signaled the interest of Big Pharma in the psychedelic sector, adding that it believes more partnerships in the space could be on the way. As reported on January 5 this year by Mindset, the tie-up consists of a US$5 million upfront cash payment and operational support to develop two 2nd generation psychedelic families in Mindset's pipeline through Phase 1a and Phase 1b trials. In return, MSRD has the right of first refusal to any exclusive licensing, asset sale, or collaboration of Mindset's drugs, along with the right of first negotiation to any sale, merger or acquisition of the biotech. MSRD is an affiliate of Otsuka Pharmaceutical, a global healthcare group and subsidiary of Otsuka Holdings, which employs 47,000 people and generated a whopping US$13.3 billion in sales in 2020. "Overall, we are encouraged to see big pharma's interest in the sector and believe more partnerships could be forthcoming, with a larger transaction potentially being a catalyst for the sector," said Stifel analysts in a note.
Blue Sky Uranium Corp has announced that it will host a corporate webinar for investors on January 12, 2022, between 4 pm to 5.05 pm ET. Investors can register for the live webinar and alerts to the replay by clicking the link here. Blue Sky Uranium Inc’s Amarillo Grande uranium and vanadium project in Argentina. The diversified project consists of three properties - Ivana, Anit and Santa Barbara. Additionally, to the south in the Chubut province of Argentina Blue Sky has three projects - Sierra Colonia, Tierras Coloradas and Cerro Parva. Combined, the company’s assets in both provinces comprise 450,000 hectares of mining tenures.
BioSig Technologies Inc, which is commercializing a signal processing platform to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, revealed that the medical tech company will be presenting at the three-day 27th Annual International Atrial Fibrillation Symposium starting on January 13, 2022. Clinical observations collected with BioSig’s PURE EP System will be presented by DJ Lakkireddy, a doctor at Kansas City Heart Rhythm Institute at HCA Midwest Health during the spotlight session on January 13, 2022, from 8.30 am-to-9.30 am ET. “Dr. Lakkireddy is highly regarded for his passionate commitment to those suffering from complex arrhythmias and for his leadership in the field of electrophysiology, and we are thrilled to have him represent our technology at this benchmark industry event,” said BioSig CEO Kenneth L Londoner. During the event, BioSig will be exhibiting at booth 403.
Milestone Scientific Inc (NYSE:MLSS) has announced that Arjan Haverhals, its chief executive officer will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022. Milestone’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, January 10, 2022, at 7.00am Eastern Time. A webcast of the company’s presentation can be accessed here and on the investor relations section of the Milestone website at https://www.milestonescientific.com/investors as of 7.00am Eastern Time on Monday, January 10, 2022.
The Valens Company (TSX:VLNS, OTCQX:VLNCF) Inc has announced that Tyler Robson, its chief executive officer and chair will participate in the ATB Capital Markets 10th Annual Institutional Investor Conference being held on January 13, 2022. Management will also be participating in a day of buyside meetings. Robson is scheduled to join Frederico Gomes, Vice President Institutional Research, for a fireside chat titled "Model Evolution Supports Margin Expansion" on Thursday, January 13, 2022, at 1.20pm ET. Investors can sign up for the virtual conference here: https://wsw.com/webcast/atb4/register.aspx?conf=atb4&page=vlns&url=https://wsw.com/webcast/atb4/vlns/1613505